Lipoprotein Apheresis

Issue link: http://cbcnybc.uberflip.com/i/862992

Contents of this Issue


Page 0 of 0

The New York Blood Center Clinical Aphereis Service is now offering Lipoprotein Apheresis (LP-APHE) as part of its mobile apheresis services. LP-APHE will be performed using the Liposorber ® MA-03 System (Kaneka Pharma America). LP-APHE is a type of selective apheresis by which atherogenic lipoproteins (such as LDL and Lp(a)) are efficiently removed while most other proteins (including the atheroprotective HDL) are not. This is in contrast to therapeutic plasma exchange (TPE) where all plasma proteins are lost with the removed plasma, and a replacement fluid is required. Conditions treated with LP-APHE include hyperlipoproteinemias such as Familial Hypercholesterolemia (FH), elevated Lp(a), and other high risk lipoproteinemias where patients have experienced cardio- vascular and/or cerebrovascular events. It is also use to treat certain sub-populations of patients with focal segmental glomerulosclerosis (FSGS). LIPOPROTEIN APHERESIS FOR MORE INFORMATION ON LP-APHE THERAPY, CONTACT NYBC CLINICAL SERVICES: 914.784.4602 REFERENCES Schwartz, J., A. Padmanabhan, et al. (2016). "Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue." Journal of Clinical Apheresis 31(3): 149-338. Bhoj, V. G. and B. S. Sachais (2015). "Lipoprotein apheresis." Curr Atheroscler Rep 17(7): 516. Heigl, F., R. Hettich, et al. (2015). "Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany." Atherosclerosis Supplements 18(0): 154-162. Muso, E. (2014). "Beneficial effect of LDL-apheresis in refractory nephrotic syndrome." Clin Exp Nephrol 18(2): 286-290. NEW YORK BLOOD CENTER'S CLINICAL APHERESIS SERVICE IS ONE OF THE FIRST IN THE NATION TO OFFER LIPOPROTEIN APHERESIS (LP-APHE) AS PART OF ITS MOBILE APHERESIS SERVICES. C L I N I C A L S E RV I C E S / 3 1 0 E A S T 6 7 T H S T R E E T / N E W Y O R K , N Y 1 0 0 6 5

Articles in this issue

Archives of this issue

view archives of NYBC - Lipoprotein Apheresis